17 beta-estradiol inhibition of Leydig cell regeneration in the ethane dimethylsulfonate-treated mature rat.
This study was designed to determine the effects of 17 beta-estradiol (E2) on Leydig cell development in the rat. Mature (60 to 65 days old) male rats received a single intraperitoneal injection of ethane dimethylsulfonate (EDS, 100 mg/kg body weight); untreated rats served as controls. In one series of experiments, groups of EDS-treated rats also received daily injections of either E2 (25 micrograms/100 g body weight), human chorionic gonadotropin (hCG, 20 IU/day), a combination of the two, or vehicle only (EDS controls). Animals were killed on days 2, 4, 10, 16, 24, 30, and 36 after EDS treatment. In another series of experiments, groups of EDS-treated rats received daily injections of hCG and E2 during days 0 through 5, 5 through 30, or 16 through 30 after EDS treatment, and were killed on day 30. In both series of experiments, the steroidogenic capacity and hCG binding capacity of the Leydig cells were examined in short-term in vitro incubations using collagenase-dispersed interstitial cells. Testes were also prepared and examined histologically by light and electron microscopy. E2 treatment of animals during the initial 5 days after EDS administration had no effect on the regeneration of interstitial cells and Leydig cells. Treatment with E2 during days 5 to 30 post-EDS blocked the regeneration of Leydig cells and thereby significantly reduced the increase in interstitial cell numbers. Finally, when E2 treatment was delayed until 16 days post-EDS, there was no significant reduction in the regeneration of interstitial or Leydig cells. These data suggest that an important developmental process that is necessary for Leydig cell regeneration occurs between days 5 and 16 post-EDS.(ABSTRACT TRUNCATED AT 250 WORDS)
Abney
T O
TO
Department of Physiology and Endocrinology, Medical College of Georgia, Augusta 30912.
Myers
R B
RB
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology*; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007985:Leydig Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008698:Mesylates / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012038:Regeneration / Q000187:drug effects* / Q000502:physiology; D013737:Testis / Q000033:anatomy & histology / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism
D006063:Chorionic Gonadotropin; D004967:Estrogens; D008698:Mesylates; D013739:Testosterone; D004958:Estradiol; C002994:ethylene dimethanesulfonate